Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Elsevier uses machine learning to benefit pharmacovigilance
Posted on November 7th, 2019 by Xuanyan Xu in Pharmacovigilance
Monitoring the scientific literature for adverse drug reactions (ADRs) is critical to maintaining drug safety, and there is no room for error. As regulations tighten, pharmacovigilance teams are seeking better strategies and methods for ensuring that all ADRs are identified in the most effective and efficient way possible.
Elsevier is providing leadership in this area in many ways, including efforts to use AI and natural language processing (NLP) technology to monitor the literature. Umesh Nandal, an Elsevier scientist who specializes in machine learning and NLP, and his team has been doing great work on the automated extraction of ADRs from biomedical literature and FDA drug labels. As a part of our outreach to the global pharmacovigilance community, I will be presenting on this work at the China Pharmacovigilance Conference in Guangzhou this month.
The presentation, which touches on the future of AI and how Elsevier is utilizing machine learning with its various information solutions, will focus on explaining various approaches for extracting ADRs and highlight a few particular projects where Elsevier is applying AI.
We are excited to be at the forefront of these developments in the use of state-of-the-art technology to meet the needs of pharmacovigilance professionals.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Sr. Marketing Manager, Life Sciences Audience at Elsevier
- 3 issues global pharmas should consider as the coronavirus outbreak continues
- Life science community shares research to combat coronavirus
- Webinar: Using machine learning to identify adverse events from scientific literature
- Elsevier supports Amsterdam’s AI initiatives
- Life Sciences trends that make me excited for 2020 (and beyond)